Drug Profile
Research programme: retinoid X receptor agonists - Connexios
Alternative Names: CNX 013; CNX 016; CNX 017; CNX-013-B2; CNX-015; CNX-018; CNXFC 010; RXR agonists - ConnexiosLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Connexios Life Sciences
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor agonists; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dyslipidaemias in India
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in India
- 09 May 2014 Preclinical development is ongoing in India